| Filed On | Filing |
|---|---|
| 09 Aug 2022 |
8-K/A: Financial Statements and Exhibits
On April 12, 2022, Halozyme Therapeutics, Inc. (the “Buyer”, “Halozyme”, “Parent”, “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Antares Pharma, Inc., a Delaware corporation (the “Seller” or “Antar... |
| 02 Nov 2021 |
8-K/A: Results of Operations and Financial Condition
– Record Quarterly Royalties in the Third Quarter of $58.6 million Representing 145% Growth over Third Quarter 2020 – |
| 12 Nov 2019 |
8-K/A: Costs Associated with Exit or Disposal Activities; Material Impairments
As previously disclosed on the Initial 8-K, on October 30, 2019, the Board of Directors of the Company approved a corporate restructuring to halt development activities for PEGPH20 and close the Company’s oncology operations. This decisi... |
| 07 Jan 2015 |
8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure
On January 7, 2015, Halozyme, Therapeutics, Inc. (“Halozyme”) issued a press release containing information concerning its cash, cash equivalents and marketable securities (unaudited) at December 31, 2014. A copy of that press release is... |
| 20 Feb 2007 |
8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “***.” AN UNREDACTED VERSION OF THIS |
| 15 Dec 2006 |
8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
THIS LICENSE AND COLLABORATION AGREEMENT (“Agreement”) dated as of December 5, 2006 (“Effective Date”), is entered into between HALOZYME, INC., a California corporation (“Halozyme”), having a place of business at 11588 Sorrento Valley Ro... |
| 20 May 2004 |
8-K/A: Changes in Control of Registrant
The Board of Directors and Shareholders DeliaTroph Pharmaceuticals, Inc. |
Loading...